Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 12Active not recruiting 5Withdrawn 1Terminated 1Not yet recruiting 1Available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Recurrence 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Thrombocytopenia 1Sinusitis 1Rib Fractures 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Non-Muscle Invasive Bladder Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, B-Cell 1Lymphoma 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Biphenotypic, Acute 1Leukemia 1Glioblastoma 1Desmoid Tumors 1Cytopenia 1Communication Disorders 1Colorectal Neoplasms 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Non-Muscle Invasive Bladder Neoplasms × 30 days × Clear all
NCT07551544 2026-05-19

ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

ImmunityBio, Inc.

Phase 3 Withdrawn
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡